Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Talks Up Emerging Markets, Especially China, As One Salve For Its Problems

This article was originally published in PharmAsia News

Executive Summary

Insisting they are not playing catch up overseas, Eli Lilly executives outlined plans for growing their business in the so-called emerging markets that are now a hot terrain - and a familiar phrase - among the biggest drug makers

You may also be interested in...



Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China

Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China

Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China

Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China

Eli Lilly Global External R&D Director Yetunde Taiwo On Partnering Plans For Discovery Research: An Interview With PharmAsia News

Yetunde Taiwo, Eli Lilly's global external R&D director, is on a global hunt for molecules that can bolster Lilly's research efforts and arm it with novel therapies. Eli Lilly spends more than $3.4 billion on research every year and prides itself on being a pioneer in collaborating with scientists to bring drugs into the market. Over the last two years, Eli Lilly struck research alliances with at least four Indian companies and has increased its activities in Asia (PharmAsia News, Oct 27, 2008). Taiwo sat down with PharmAsia News' India bureau to give a lowdown on Lilly's risk-sharing strategy to shore up its new chemical entities.

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel